Cost-effectiveness of a novel hybrid closed-loop system compared with continuous subcutaneous insulin infusion in people with type 1 diabetes in the UK

References

• Patterson CC, Karuranga S, Salpea P, et al. Worldwide estimates of incidence, prevalence and mortality of type 1 diabetes in children and adolescents: results from the international diabetes federation diabetes Atlas. Diabetes Res Clin Pract. 2019;157:107842.
   PubMed Web of Science ®Google Scholar
• Bommer C, Sagalova V, Heesemann E, et al. Global economic burden of diabetes in adults: projections from 2015 to 2030. Dia Care. 2018;41(5):963–970.
   PubMed Web of Science ®Google Scholar
• National Institute for Health Research Horizon Scanning Research and Intelligence Centre. MiniMed 670G Hybrid closed loop system for type 1 diabetes. 2017. Available at: http://www.io.nihr.ac.uk/wp-content/uploads/migrated/MiniMed-670G-HCL-for-type-1-diabetes-FINAL.pdf [cited 2020 Oct 19]
   Google Scholar
• Raymakers AJN, Gillespie P, O’Hara MC, et al. Factors influencing health-related quality of life in patients with type 1 diabetes. Health Qual Life Outcomes. 2018;16(1):27.
   PubMed Web of Science ®Google Scholar
• Rosner B, Roman-Urrestarazu A. Health-related quality of life in paediatric patients with type 1 diabetes mellitus using insulin infusion systems. A systematic review and meta-analysis. PLOS One. 2019;14(6):e0217655.
   PubMed Web of Science ®Google Scholar
• Akturk HK, Giordano D, Champakanath A, et al. Long-term real-life glycaemic outcomes with a hybrid closed-loop system compared with sensor-augmented pump therapy in patients with type 1 diabetes. Diabetes Obes Metab. 2020;22(4):583–558.
   PubMed Web of Science ®Google Scholar
• Lepore G, Scaranna C, Corsi A, et al. Switching from suspend-before-low insulin pump technology to a hybrid closed-loop system improves glucose control and reduces glucose variability: a retrospective observational case-control study. Diabetes Technol Ther. 2020;22(4):321–325.
   PubMed Web of Science ®Google Scholar
• Duffus SH, Ta’ani ZA, Slaughter JC, et al. Increased proportion of time in hybrid closed-loop "auto mode" is associated with improved glycaemic control for adolescent and young patients with adult type 1 diabetes using the MiniMed 670G insulin pump. Diabetes Obes Metab. 2020;22(4):688–693.
   PubMed Web of Science ®Google Scholar
• Nathan DM. The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview. Dia Care. 2014;37(1):9–16.
   PubMed Web of Science ®Google Scholar
• Diabetes Control and Complications Trial (DCCT)/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group. Mortality in type 1 diabetes in the DCCT/EDIC versus the general population. Diabetes Care. 2016;39(8):1378–1383.
   PubMed Web of Science ®Google Scholar
• Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of time in range as an outcome measure for diabetes clinical trials. Dia Care. 2019;42(3):400–405.
   PubMed Web of Science ®Google Scholar
• Currie CJ, Morgan CL, Poole CD, et al. Multivariate models of health-related utility and the fear of hypoglycaemia in people with diabetes. Curr Med Res Opin. 2006;22(8):1523–1534.
   PubMed Web of Science ®Google Scholar
• Huo L, Harding JL, Peeters A, et al. Life expectancy of type 1 diabetic patients during 1997–2010: a national Australian registry-based cohort study. Diabetologia. 2016;59(6):1177–1185.
   PubMed Web of Science ®Google Scholar
• Garg SK, Weinzimer SA, Tamborlane WV, et al. Glucose outcomes with the in-home use of a hybrid closed-loop insulin delivery system in adolescents and adults with type 1 diabetes. Diabetes Technol Ther. 2017;19(3):155–163.
   PubMed Web of Science ®Google Scholar
• Stone MP, Agrawal P, Chen X, et al. Retrospective analysis of 3-month real-world glucose data after the minimed 670g system commercial launch. Diabetes Technol Ther. 2018;20(10):689–692.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Technology appraisal guidance TA151. Continuous subcutaneous insulin infusion for the treatment of diabetes mellitus. Available at: https://www.nice.org.uk/guidance/ta151/chapter/1-Guidance [cited 2020 Oct 19].
   Google Scholar
• Association of British Clinical Diabetologists. Standards of care for management of adults with type 1 diabetes. 2016. Available at: http://www.diabetologists-abcd.org.uk/Position_Papers/Type_1_standards_of_care.pdf [cited 2020 Oct 19].
   Google Scholar
• Sherr JL, Hermann JM, Campbell F, et al. T1D exchange clinic network, the DPV initiative, and the national paediatric diabetes audit and the royal college of paediatrics and child health registries. Use of insulin pump therapy in children and adolescents with type 1 diabetes and its impact on metabolic control: comparison of results from three large, transatlantic paediatric registries. Diabetologia. 2016;59(1):87–91.
   PubMed Web of Science ®Google Scholar
• National Diabetes Insulin Pump Audit. 2017–2018. England and Wales, 8 August 2019. Available at: https://files.digital.nhs.uk/DF/2ACADD/National%20Diabetes%20Insulin%20Pump%20Audit%202017-18%20Report.pdf [cited 2020 Oct 19].
   Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. The CORE diabetes model: projecting long-term clinical outcomes, costs and cost-effectiveness of interventions in diabetes mellitus (types 1 and 2) to support clinical and reimbursement decision-making. Curr Med Res Opin. 2004;20(sup1):S5–S26.
   PubMed Web of Science ®Google Scholar
• Palmer AJ, Roze S, Valentine WJ, et al. Validation of the CORE diabetes model against epidemiological and clinical studies. Curr Med Res Opin. 2004;20(Suppl 1):S27–S40.
   PubMed Web of Science ®Google Scholar
• McEwan P, Foos V, Palmer JL, et al. Validation of the IMS CORE diabetes model. Value Health. 2014;17(6):714–724.
   PubMed Web of Science ®Google Scholar
• Bergenstal RM, Garg S, Weinzimer SA, et al. Safety of a hybrid closed-loop insulin delivery system in patients with type 1 diabetes. JAMA. 2016;316(13):1407–1408.
   PubMed Web of Science ®Google Scholar
• Östenson CG, Geelhoed-Duijvestijn P, Lahtela J, et al. Self-reported non-severe hypoglycaemic events in Europe. Diabet Med. 2014;31(1):92–101.
   PubMed Web of Science ®Google Scholar
• Leiter LA, Yale J-F, Chiasson J-L, et al. Assessment of the impact of fear of hypoglycemic episodes on glycemic and hypoglycemia management. Can J Diabetes. 2005;29:186–192.
   Google Scholar
• National Institute for Health and Care Excellence. National Clinical Guideline Center. 2015. Clinical guideline NG17, type 1 diabetes in adults: diagnosis and management. Available at: https://www.nice.org.uk/guidance/ng17/evidence/appendices-hu-pdf-435400240 [cited 2020 Oct 19].
   Google Scholar
• NHS reference costs. 2020. Available at: https://improvement.nhs.uk/resources/reference-costs/#rc1718 [cited 2020 Oct 19]
   Google Scholar
• Guest JF, Fuller GW, Vowden P. Diabetic foot ulcer management in clinical practice in the UK: costs and outcomes. Int Wound J. 2018;15(1):43–52.
   PubMed Web of Science ®Google Scholar
• Hammer M, Lammert M, Mejías SM, et al. Costs of managing severe hypoglycaemia in three European countries. J Med Econ. 2009;12(4):281–290.
   PubMedGoogle Scholar
• Beaudet A, Clegg J, Thuresson PO, et al. Review of utility values for economic modeling in type 2 diabetes. Value Health. 2014;17(4):462–470.
   PubMed Web of Science ®Google Scholar
• Evans M, Khunti K, Mamdani M, et al. Health-related quality of life associated with daytime and nocturnal hypoglycaemic events: a time trade-off survey in five countries. Health Qual Life Outcomes. 2013;11(1):90.
   PubMed Web of Science ®Google Scholar
• Marrett E, Radican L, Davies MJ, et al. Assessment of severity and frequency of self-reported hypoglycemia on quality of life in patients with type 2 diabetes treated with oral antihyperglycemic agents: a survey study. BMC Res Notes. 2011;4(1):251.
   PubMedGoogle Scholar
• Nørgaard K, Scaramuzza A, Bratina N, et al. Sensor-augmented pump therapy in real-life: patients reported outcomes results of the INTERPRET observational study. Abstract. Berlin: EASD; 2012. p. 1058.
   Google Scholar
• Nørgaard K, Scaramuzza A, Bratina N, et al. Interpret Study Group. Routine sensor-augmented pump therapy in type 1 diabetes: the INTERPRET study. Diabetes Technol Ther. 2013;15:273–280.
   PubMed Web of Science ®Google Scholar
• Yeh HC, Brown TT, Maruthur N, et al. Comparative effectiveness and safety of methods of insulin delivery and glucose monitoring for diabetes mellitus: a systematic review and meta-analysis. Ann Intern Med. 2012;157(5):336–347.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence. Guide to the methods of technology appraisal 2013. Section 5 The reference case. 2013. Available at: https://www.nice.org.uk/process/pmg9/chapter/the-reference-case#discounting [cited 2020 Oct 19]
   Google Scholar
• McCabe C, Claxton K, Culyer AJ. The NICE cost-effectiveness threshold: what it is and what that means. Pharmacoeconomics. 2008;26(9):733–744.
   PubMed Web of Science ®Google Scholar
• Jendle J, Pöhlmann J, de Portu S, et al. Cost-effectiveness analysis of the MiniMed 670G hybrid closed-loop system versus continuous subcutaneous insulin infusion for treatment of type 1 diabetes. Diabetes Technol Ther. 2019;21(3):110–118.
   PubMed Web of Science ®Google Scholar
• Driscoll KA, Raymond J, Naranjo D, et al. Fear of hypoglycemia in children and adolescents and their parents with type 1 diabetes. Curr Diab Rep. 2016;16(8):77.
   PubMed Web of Science ®Google Scholar
• Jabbour G, Henderson M, Mathieu ME. Barriers to active lifestyles in children with type 1 diabetes. Can J Diabetes. 2016;40(2):170–172.
   PubMed Web of Science ®Google Scholar
• Fulcher G, Singer J, Castañeda R, et al. The psychosocial and financial impact of non-severe hypoglycemic events on people with diabetes: two international surveys. J Med Econ. 2014;17(10):751–761.
   PubMedGoogle Scholar
• Ng SM, Moore HS, Clemente MF, et al. Continuous glucose monitoring in children with type 1 diabetes improves well-being, alleviates worry and fear of hypoglycemia. Diabetes Technol Ther. 2019;21(3):133–137.
   PubMed Web of Science ®Google Scholar
• Grando MA, Bayuk M, Karway G, et al. Patient perception and satisfaction with insulin pump system: pilot user experience survey. J Diabetes Sci Technol. 2019;13(6):1142–1148.
   PubMedGoogle Scholar
• Farrington C. Psychosocial impacts of hybrid closed-loop systems in the management of diabetes: a review. Diabet Med. 2018;35(4):436–449.
   PubMed Web of Science ®Google Scholar
• Diabetes Times. Teenager receives first commercial artificial pancreas. 2018. Available at: https://diabetestimes.co.uk/teenager-receives-first-commercial-artificial-pancreas/ [cited 2020 Oct 19]
   Google Scholar
• Pickup JC, Ford Holloway M, Samsi K. Real-time continuous glucose monitoring in type 1 diabetes: a qualitative framework analysis of patient narratives. Diabetes Care. 2015;38(4):544–550.
   PubMed Web of Science ®Google Scholar
• Diabetes.co.uk Medtronic’s closed-loop MiniMed 670G now available on NHS in some areas. Available at: https://www.diabetes.co.uk/news/2019/mar/medtronic's-closed-loop-minimed-670g-now-available-on-nhs-in-some-areas-99233687.html [cited 2019 Aug 12].
   Google Scholar
• American Diabetes Association Consensus Panel. Guidelines for computer modeling of diabetes and its complications. Diabetes Care. 2004;27:2262–2265.
   PubMed Web of Science ®Google Scholar
• Runge AS, Kennedy L, Brown AS, et al. Does time-in-range matter? Perspectives from people with diabetes on the success of current therapies and the drivers of improved outcomes. Clin Diabetes. 2018;36(2):112–119.
   PubMedGoogle Scholar
• Brod M, Christensen T, Thomsen TL, et al. The impact of non-severe hypoglycemic events on work productivity and diabetes management. Value Health. 2011;14(5):665–671.
   PubMed Web of Science ®Google Scholar